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Abstract: The major arboviral diseases in mainland China
include Japanese encephalitis, dengue fever, Crimean-
Congo hemorrhagic fever (also known as Xinjiang
hemorrhagic fever), and tick-borne encephalitis. These
and other newly found arbovirus infections due to Banna
virus and Tahyna virus contribute to a large and relatively
neglected disease burden in China. Here we briefly review
the literature regarding these arboviral infections in
mainland China with emphasis on their epidemiology,
primary vectors, phylogenetic associations, and the
prevention programs associated with these agents in
China.
Introduction
Arboviruses (arthropod-borne viruses) are maintained in nature
in cycles involving hematophagous arthropod vectors and
susceptible vertebrate hosts [1]. At present, more than 550
arboviruses have been identified, among which are more than 130
virus species that can cause disease in susceptible vertebrate hosts
[2]. Japanese encephalitis virus (JEV), dengue virus (DENV),
Crimean-Congo hemorrhagic fever virus (CCHFV) (also known as
Xinjiang hemorrhagic fever virus, XHFV), and tick-borne
encephalitis virus (TBEV) are the four principal arboviruses of
public health importance in mainland China at present [3]. There
is a growing body of evidence indicating that other arboviruses are
present and causing human infections and diseases in China. In
this review, we summarize relevant information available in the
Chinese scientific literature, highlight the current situation of
arboviral infections in mainland China, and describe current
practices and recommendations regarding surveillance and
prevention measures.
Japanese Encephalitis
Japanese encephalitis (JE) is arguably the world’s single most
important acute viral encephalitis accounting for 30,000–50,000
cases and 10,000–15,000 deaths each year, with survivors often
experiencing irreversible neurological damage [4,5,6]. By some
estimates, the number of cases caused by JEV may be as high as
175,000 each year [7]. JEV is a mosquito-transmitted flavivirus
that is concentrated in China, India, and Southeast Asia, where it
is the leading cause of viral neurologic disease with an incidence
exceeding that of herpes simplex virus [8]. The virus is maintained
in a cycle involving birds and Culex mosquitoes. In Asia, an
epizootic cycle involving domestic pigs and Culex tritaeniorhynchus
mosquitoes is associated with high incidence of human disease in
rural areas [9]. Historically, JE prevalence has been high in China,
where major outbreaks occurred in 1966 and 1971 with reported
disease incidence of .15/100,000 and 20.92/100,000, respec-
tively [10]. After the nationwide vaccination program initiated in
the 1970s, the number of reported cases dramatically decreased,
with disease incidence declining from 20.92/100,000 in 1971 to
0.23/100,000 in 2008 (Figure 1) [11].
Virus and Vectors
Nucleotide sequencing of the JEV envelope protein genes has
identified five genotypes (GI, GII, GIII, GIV, and GV) [12]. Of
these, GI and GIII of JEV circulate in China. GIII was widespread
before 2000 while GI has been isolated from Yunnan, Shanghai,
Liaoning, Sichuan, Henan, and Gansu provinces in recent years
[13]. Both GI and GIII of JEV were detected from cerebrospinal
fluids (CSF) of patients and mosquitoes simultaneously during a JE
outbreak in Yuncheng City, Shanxi province in 2006 [14]. Culex
tritaeniorhynchus is the primary vector of JEV in China, though the
virus has been isolated from more than 20 other mosquito species.
JEV also has been isolated from Culicoides and fruit bats in China
[15,16].
Epidemiology
Human JE cases have been reported from all provinces with the
exception of Xinjiang Uygur Autonomous Region (hereinafter
referred to as Xinjiang), Tibet Autonomous Region (hereinafter
referred to as Tibet), and Qinghai province in the western regions
of China (Figure 2). JE epidemic areas can be divided into
categories of high, medium, and low prevalence. Using case
reports from 1998–2002, high prevalence areas include Shaanxi
province, Chongqing municipality in Sichuan province, Sichuan
province, Guizhou province, Henan province, and Yunnan
province where JE incidence is over 1/100,000. JE medium
prevalence areas include Anhui province, Hubei province, Hunan
province, Jiangxi province, and Guangxi province where inci-
dence is 0.5–1/100,000. In low prevalence areas such as Gansu
province, Jiangsu province, Shandong province, Fujian province,
Guangdong province, and Zhejiang province, the incidence is
below 0.5/100,000. From historical and current data, it appears
that high prevalence areas have shifted from eastern coastal areas
to the central and western regions in the last 50 years [10]. Since
2000, the number of JE cases reported in China has decreased
every year, with the exception of 2006 when the number of cases
increased approximately 50% over the previous year.
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www.plosntds.org 1 April 2010 | Volume 4 | Issue 4 | e624JE cases occur during every month of the year in mainland
China, while cases reported in winter are only from southern
provinces. Generally, case reports begin to increase in May, peak
in July and August, and decrease in September [17,18]. During
2004–2006, the period from June to September accounted for
94.9%–98.1% of all cases within the year while July to August
Figure 1. JE incidence from 1951–2008 in mainland China.
doi:10.1371/journal.pntd.0000624.g001
Figure 2. Distribution of mosquito-borne diseases in mainland China. Map 1 shows the distribution of JE and DEN. Map 2 shows the case
distribution of JE in 2007. Map 3 shows the case distribution of DEN in 2007.
doi:10.1371/journal.pntd.0000624.g002
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groups can be affected by JEV, but children account for most
cases. During most years, children under 15 years of age account
for 85.9%–90.6% of reported JE cases [10,17]. However, an
exception to this pattern occurred during the JE outbreak in
Yuncheng city in 2006 when more than 86% of the patients were
.30 years of age, with only 10% of patients ,7 years of age [10].
Males are infected more frequently than females with a ratio 1.37–
1.60:1 probably because of more outdoor activity by males [18].
Prevention and Recommendations
An inactivated JE vaccine derived from the P3 strain of JEV was
developed in 1968 and was provided to populations at high risk in
China [19]. In 1988 a live attenuated vaccine (based on the SA 14-
14-2 strain) was licensed for use in China after studies had
demonstrated its safety and high efficacy [20]. Currently, both
vaccines are used nationwide and the vaccine program is largely
credited with the reductions in cases that have been observed [21].
In 2007 the Chinese government announced its intention to include
JE vaccine in the expanded project of immunization in order to
further enhance the prevention and control of JE. Although great
successhasbeen achievedbythevaccinationprogram,anenhanced
JE surveillance system, including investigation of infection rates in
vectors, should be implemented to better describe the burden of
disease and risk factors for JE infection in different areas of the
country. In addition, JE vaccination rates and immune responses
following vaccination warrant further investigation.
Dengue
Dengue (DEN) is caused by four serotypes of DENV that occur
in over 100 countries and threaten the health of more than 2.5
billion people in urban, peri-urban, and rural areas of the tropics
and subtropics [22]. DENV can cause a spectrum of illness
ranging from dengue fever to the more serious dengue
hemorrhagic fever/dengue shock syndrome (DHF/DSS) [23].
Worldwide, the virus causes about 50 to 100 million dengue
infections each year, all of which may not present clinically as
dengue fever. The estimates of DHF/DSS are close to 500,000
cases [24]. In China, dengue epidemics have occurred mainly in
the southern regions of the country, primarily in Guangxi
province, Guangdong province, Fujian province, Zhejiang prov-
ince, and Hainan province (Figure 2).
Virus and Vectors
All four serotypes of DENV have caused outbreaks in China.
Large outbreaks were caused by DENV-4 in 1978 in Guangdong
province, DENV-1 and DENV-3 in 1980 in Hainan province, and
DENV-2 in 1986 in Hainan province [25,26,27].
The mosquito species Aedes aegypti and Aedes albopictus are the
primary vectors of DENV in China. Aedes aegypti is the vector in
coastal areas and is mainly distributed in Hainan province and
found sporadically in Guangdong province and Guangxi province
[28]. Aedes albopictus is the vector in inland regions and is
widespread in mainland China. This species is distributed from
Liaoning province in the north to Shaanxi province in the
northwest and from Tibet in the southwest to the southern reaches
of China beyond the Yangtze River [29]. In addition to detecting
virus in the mosquito vectors, a study reported that DENV RNA
has been detected using RT-PCR in the brain tissue of Rousettus
leschenaultia, a fruit bat collected in Hainan province [30].
Moreover, antibodies to DENV were detected in Rousettus
leschenaultia collected in Yunnan province during a study of dengue
fever in the region [31].
Epidemiology
In the early 1940s, DENV was epidemic on the southeastern
coast of China and the middle and lower reaches of the Yangtze
River [32]. There were no reported cases of DEN in China from
1946 to 1978. The reason for this phenomenon is unclear. In
1978, an epidemic caused by DENV-4 occurred in Foshan City of
Guangdong province [25]. The outbreak affected seven neigh-
boring counties, lasted 8 months, and resulted in 22,122 cases and
14 deaths. A dengue outbreak involving 13 cities and counties
occurred in Hainan province in 1980, during which DENV-3 was
isolated from acute-phase sera and adult Ae. aegypti [26]. This
outbreak caused 437,468 cases and 64 deaths [33]. In 1985–1986,
DHF was reported in Hainan province. This outbreak was caused
by DENV-2 and produced considerable morbidity and high
mortality, with 113,589 cases and 289 deaths [27,33].
Since the 1990s, dengue epidemics have frequently occurred in
Guangdong province, Guangxi province, and Fujian province.
The outbreaks of dengue fever in China usually resulted from the
introduction of the virus by infected travelers and refugees from
various areas of southeastern Asia where dengue is endemic. For
example, an outbreak of DENV-1 in Zhejiang province in 2004
was associated with a traveler from Thailand [34]. This outbreak
caused a total of 82 reported cases. Epidemiological investigation
of cases reported from Guangdong showed that cases reported
from 1990 to 2006 were mostly imported or occurred in local
epidemics initiated by imported cases [35,36]. Nationwide in
China, the number of reported cases has varied considerably,
ranging from 40 in 2005 to 1,044 in 2006 with the incidence
ranging as high as 5.7/1,000,000 over the period from 1990–2008
(Figure 3).
Though Yunnan province is adjacent to Vietnam, Thailand,
and Myanmar where DEN is endemic, Aedes albopictus is relatively
common in the southwestern part of the province, and DENV has
been isolated from this species in the areas [37,38], there have
been relatively few DEN cases reported from Yunnan. However,
increasing travel and commerce between Yunnan and the
neighboring dengue epidemic countries increases the likelihood
of imported dengue, which could become an important factor
influencing dengue epidemiology in Yunnan in the future.
The epidemic season for DENV occurs mainly in the rainy, hot
summer and autumn, which correlates with the seasonal
periodicity of the vectors. Most cases are reported from March
to November with a peak in July to September, while Hainan
province has cases throughout the year with a peak in July to
October [39]. Statistical analysis of incidence rates of age groups
in different years showed that, in general, the highest incidence
was in the 10- to 39-year-old group [40].
Prevention and Recommendations
In the absence of an effective vaccine against DENV, vector
management is the only prevention tool available. In China,
vector control includes programs in community participation and
health education to reduce mosquito breeding in household water
containers. At present, a vector surveillance system has only been
established in Guangxi province, Guangdong province, Fujian
province, Yunnan province, and Hainan province. Vector-based
surveillance should be established nationwide to determine the
distribution of competent vector species and to identify areas that
may be at risk if mosquito distributions shift in response to climate
change. In view of the current status of a large number of
imported cases, it is crucial to provide health education targeted at
the high risk groups including travelers from dengue epidemic
countries in order to prevent importation of dengue fever. In
addition, considering the increased travel between Southeast Asia
www.plosntds.org 3 April 2010 | Volume 4 | Issue 4 | e624and China, more surveillance is necessary to monitor DEN
epidemiology in the region.
Crimean-Congo Hemorrhagic Fever
CCHFV is a tick-borne virus in the genus Nairovirus, family
Bunyaviridae that produces a severe hemorrhagic fever and a
potentially fatal outcome [41]. CCHFV has the most extensive
geographic distribution of the medically important tick-borne viral
diseases and the CCHFV infection has been described in parts of
Africa, the Middle East, Eastern Europe, and Asia [41]. CCHFV
causes severe disease in human beings with a reported mortality
rate of 3%–30% [42]. Global disease burden is difficult to
determine, however the incidence of sporadic cases and outbreaks
of Crimean-Congo hemorrhagic fever (CCHF) is reported to have
increased across the endemic region during the past decade [43].
The apparent increase in incidence possibly reflects both greater
human exposure to infected ticks and more widespread recogni-
tion of the disease by health care workers [44]. In China, CCHF
was first described in Bachu County along the Tarim river basin in
Xinjiang in 1965. CCHFV was first isolated in 1966 in Xinjiang
from the blood of patients, organs from autopsy, and the tick
Hyalomma asiaticum [45,46]. Based on the site of isolation in China,
CCHF and CCHFV are referred to as XHF and XHFV in the
Chinese literature [45].
Virus and Vectors
Phylogenetic analysis of the S-RNA sequence showed that
strains isolated from Xinjiang form a separate branch with isolates
from its border regions (Tajikistan, Uzbekistan, and Kazakhstan).
This suggests that CCHFV has developed a unique and possibly
isolated focus of transmission in Xinjiang and its border regions
[47]. The latest sequence information of CCHFV from China was
obtained in a tick-borne arbovirus investigation in 2004 [48]. The
phylogenetic analysis of partial L gene sequence of CCHFV
showed CCHFV isolated in Xinjiang in 2004 has a distant
evolutionary relationship to an African strain of CCHFV but a
close relationship to central Asian strains from Pakistan and
Tajikistan [48].
Hyalomma asiaticum kozlovi, a subspecies of Hyalomma asiaticum,i s
the main vector of CCHFV in China. The most active season for
adult ticks is from early April to early May, which coincides with
the epidemic season of CCHF and is also the busiest season for
work in the pastures in this region. The virus can be transmitted to
humans by the bite of infected ticks or by direct contact with blood
and tissues from viremic livestock or patients. For example, there
has been one report of a possible horizontal transmission from a
mother to her child in Xinjiang [49]. So the latter route of
transmission indicates that preventive measures should be used by
farmers working with sick livestock as well as by caregivers to
reduce the risk of human-to-human transmission.
Epidemiology
To date in China, CCHF cases have only been reported from
Xinjiang (Figure 4). However, specific antibodies to CCHFV have
been detected in the serum of livestock and humans in areas such
as Qinghai province, Inner Mongolia Autonomous Region
(hereinafter referred to as Inner Mongolia), Sichuan province,
Yunnan province, Hainan province, and Anhui province, which
implies that there may be other areas of CCHFV transmission in
mainland China [50]. Almost all CCHF cases occur from late
March to mid-June with peaks in April and May [50]. Patients are
primarily middle-aged male ranchers.
Bachu County in Xinjiang reports most of the CCHF cases in
the region, probably because the ecology of the area is semi-desert
and is suitable habitat for the vector ticks. From 1965 to 2002, 230
cases were reported from Bachu County with an average annual
incidence of 6 [51,52]. The most serious epidemic occurred in
2001 with 51 cases and 3 deaths reported in Bachu County [52].
Since 2003, no cases have been reported from Xinjiang.
Prevention and Recommendations
Currently, there is no vaccine available in China to prevent
CCHF and the primary prevention is repelling and killing ticks.
An education program informing people about preventing tick
bites was established in Xinjiang, which may account for there
being no cases reported from this area since 2002. Additional
active surveillance using sensitive serological methods and
molecular biological methods that are currently available
[48,53,54] are required to better understand the distribution and
disease burden caused by this pathogen.
Tick-Borne Encephalitis
TBEV is tick-borne flavivirus in the family Flaviviridae.I ti s
considered one of the most dangerous human infections occurring
Figure 3. Dengue incidence from 1990–2008 in mainland China.
doi:10.1371/journal.pntd.0000624.g003
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11,000 human cases of encephalitis in Russia and about 3,000 cases
in the rest of Europe annually [55]. Tick-borne encephalitis (TBE)
has a significant mortality rate depending upon the strain of virus
and may cause long-term neurological/neuropsychiatric sequelae
[56]. TBE was first described in China in 1943 and TBEV was
isolated from patients and ticks in 1952 [57,58].
Virus and Vectors
TBEV is classified as one species with three subtypes: the
European subtype, the Siberian subtype, and the Far-Eastern
subtype [59]. Human infections with the Far-Eastern subtype
viruses are usually severe, frequently with encephalitis signs and
with a fatality rate of 20% to 40%. In contrast, the Siberian subtype
characteristically induces a less severe acute period and a high
prevalence of the nonparalytic febrile form of encephalitis; case
fatality rates rarely exceed 6% to 8%. Those following infection by
European-subtype strains are usually milder, mostly without
sequelae; case fatality rates are often as low as 1% to 2% [60].
While Ixodes ricinus is the most important vector of the European
subtype, I. persulcatus is the main vector of the other subtypes. The
main vector of TBEV in China is I. persulcatus, which is distributed
in the forest areas of northeast and northwest China, including
Liaoning province, Jilin province, Heilongjiang province, Inner
Mongolia, and Xinjiang, particularly in areas characterized as
mixed broadleaf-conifer forests.
By far, all TBEV strains isolated in China belong to the Far-
Eastern subtype [57,59]. TBEV strains have been isolated from
patients and ticks in north and north-eastern forest areas of China.
HLJ-1 strain and Senzhang strain were isolated from brain tissues
of a patient from the northeastern forests of China in 1952
and1953, respectively [58,61]. The Senzhang strain was chosen
for the vaccine strain. Also from northeastern forest habitats are
the MDJ01 strain (isolated from the sera of a TBE patient) and the
‘‘T’’ and ‘‘H’’ strains (isolated from I. persulcatus and brain tissue of
an encephalitis patient, respectively) [61,62]. More recently, six
TBE strains (DXAL-5, -12, -13, -16, -18, and -21) have been
isolated from I. persulcatus collected in forest areas of Heilongjiang
province in 2002. Phylogenetic analysis of the E protein gene
sequence showed that all six strains belong to the Far-Eastern
subtype. The homology of amino acid with Senzhang vaccine
strain is higher than 97%, indicating that the vaccine strain likely
has good protection against the new isolates [63].
Epidemiology
The distribution of TBE in China is closely related to the
distribution of the tick vectors [64]. There are two foci in mainland
China: the Northeast focus and the Xinjiang focus (Figure 4).
There is also serological evidence of TBEV in Tibet in western
China and in Yunnan located in southwestern China [65].
TBE cases emerge in late April, increase in May, and reach a
peak during late May and early June. This period positively
correlates with the active season of the tick vector; however, the
peak in human cases generally occurs 2 wk following the peak in
tick activity [66]. Almost all people infected with TBEV are forest
workers, surveyors, rhizotomists, or their family members [66].
Prevention and Recommendations
A purified virus vaccine derived from the Senzhang strain in
2001 in China has passed stage I, II, and III clinical trials. It has
good immunogenicity and notably decreased adverse effect rates
compared with inactivated mouse-brain and chicken embryo
tissue-derived vaccine developed in 1953 and inactivated chicken
embryo cell and hamster kidney cell-derived vaccine developed
from 1958 to 1967 [67,68,69]. The purified virus vaccine is now
produced and marketed in China. Besides vaccination, education
programs for preventing tick bites in the forest areas should be
implemented in the known epidemic regions.
Other Arboviruses
Many other arboviruses have been isolated from mosquito and
tick vectors, human specimens (serum, CSF, brain tissue), and
Figure 4. Distribution of tick-borne diseases in mainland China.
doi:10.1371/journal.pntd.0000624.g004
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Getah virus (GETV) [70,71], Chikungunya virus (CHIKV)
[72,73,74], Sindbis virus (SINDV) [75,76], Banna virus (BAV)
[77,78], Kyasanur forest disease virus (KFDV) [79], Liaoning virus
(LNV) [80,81], Ross river virus (RRV) [82], Batai virus (BATV)
[83,84], Kadipiro virus (KDV) [85], Tahyna virus (TAHV) [86],
and Chaoyang virus (Table 1) [87]. In addition, serosurveys have
found evidence of human infection with CHIKV [72], SINDV
[75,88], RRV [82], GETV [71,89], Semliki Forest virus [89],
Kunjun virus [89], Powassan virus [89], Langat virus [89],
Sagiyama virus [90], TAHV [86], KFDV [91,92], and BAV
[77,93]. Many of these viruses have been shown to cause various
pathologies ranging from mild fever and arthralgia to encephalitis
in humans. Specific evidence is currently lacking to demonstrate
the public health impact of these viruses in China.
However, persistence of encephalitis cases in areas where large-
scale JE vaccine programs have been implemented is suggestive of
the health burden these arboviral agents may impose [94]. The
observations described above underscore the importance of
zoonotic arboviruses and reinforce the need to conduct additional
investigations into the public health impact of arboviruses and to
better understand the epidemiology and ecology of these diseases
in mainland China.
Conclusions
Arboviral diseases, both the well known and relatively obscure,
have a great impact on public health in mainland China and have
the potential to increase in importance with changes in
demographics, land use, and climate change. However, relatively
little is known of arboviral epidemiology and transmission ecology
in much of the country. It is essential that surveillance be
implemented to evaluate and monitor the distribution and true
disease burden from arboviral etiologies. In addition, research is
needed to better identify and characterize the arboviral strains,
vectors, vertebrate hosts, and habitat parameters involved in these
complex disease ecologies. Only through accumulation of this
additional knowledge will we be able to develop and target
appropriate diagnostic services and interventions and to direct
resources to developing education programs, vaccines, and
therapeutics that may be needed to improve the capacity for
infectious disease prevention and control in China and worldwide.
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